Ratings for DexCom (NASDAQ:DXCM) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ...
In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...
In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the ...
The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more affordable way to monitor their blood sugar. The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more ...
The G7 system is now available in the U.K., Ireland, Germany, Austria and Hong Kong. Dexcom said it plans to reach outlets in South Africa and New Zealand in the weeks ahead and additional countries ...
Though it received a green light in Europe this past March, Dexcom will resubmit the G7 CGM's software for FDA review after making changes to how it delivers glucose alerts. (Dexcom) Diabetes tracker ...
Join Becker’s Healthcare Podcast as we dive into the world of continuous glucose monitoring with Scott Odgers from Dexcom. Discover how CGM devices are transforming healthcare experiences and access, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results